Protein kinase C iota
View Patent ↗The invention involves PKCι signaling. The invention provides, for example, transgenic animals, inhibitors of PKCι signaling, methods for inhibiting PKCι signaling, methods for identifying inhibitors of PKCι signaling, and methods for diagnosing cancer.
1. A transgenic mouse whose genome comprises a transgene, said transgene comprising a nucleic acid sequence encoding a constitutively active protein kinase C iota polypeptide operably linked to a liver fatty acid-binding protein promoter, wherein said transgenic mouse expresses said constitutively active protein kinase C iota polypeptide and develops more preneoplastic colonic lesions after azoxymethane treatment than a corresponding wild-type mouse treated with said azoxymethane.
2. The transgenic mouse of claim 1 , wherein the promoter is an Fabpl 4× at −132 promoter.
3. Progeny of the transgenic mouse of claim 1 , wherein the progeny have a genome comprising the transgene, and wherein said progeny expresses said constitutively active protein kinase C iota polypeptide and develop more preneoplastic colonic lesions after azoxymethane treatment than a corresponding wild-type mouse treated with said azoxymethane.
4. An isolated cell of a transgenic mouse whose genome comprises a transgene, said transgene comprising a nucleic acid sequence encoding a constitutively active protein kinase C iota polypeptide operably linked to a liver fatty acid-binding protein promoter, wherein said transgenic mouse expresses said constitutively active protein kinase C iota polypeptide and develops more preneoplastic colonic lesions after azoxymethane treatment than a corresponding wild-type mouse treated with said azoxymethane.
5. A method for identifying an agent that inhibits transformation of a cell, wherein said method comprises: (a) administering a test agent and carcinogen to transgenic mouse whose genome comprises a transgene, said transgene comprising a nucleic acid sequence encoding a constitutively active protein kinase C iota polypeptide operably linked to a liver fatty acid-binding protein promoter, wherein said transgenic mouse expresses said constitutively active protein kinase C iota polypeptide and develops more preneoplastic colonic lesions after azoxymethane treatment than a corresponding wild-type mouse treated with said azoxymethane, and (b) determining if said test agent inhibits cell transformation in said transgenic mouse as compared with a corresponding transgenic mouse to which said test agent has not been administered.
6. The method of claim 5 , comprising determining if said test agent inhibits intestinal cell transformation in said transgenic mouse as compared with a corresponding transgenic mouse to which said test agent has not been administered.
7. The method of claim 5 , wherein said test agent is a test polypeptide.
8. The method of claim 7 , wherein said test polypeptide comprises an amino acid sequence present in a protein kinase C iota polypeptide.
9. The method of claim 5 , wherein said carcinogen is azoxymethane or dimethylhydrazine.